Lamotrigine is a medication used primarily to treat two conditions: epilepsy and bipolar disorder. It is FDA-approved to control several types of seizures in people aged 2 and older, and to prevent mood episodes in adults with bipolar I disorder. Sold under the brand name Lamictal, it has become one of the most widely prescribed medications in both neurology and psychiatry.
Epilepsy and Seizure Control
Lamotrigine is approved to treat partial-onset seizures (the most common type in adults, starting in one area of the brain), primary generalized tonic-clonic seizures (affecting both sides of the brain at once), and the generalized seizures seen in Lennox-Gastaut syndrome, a severe form of childhood epilepsy. For children aged 2 and older, it is used alongside other seizure medications. For adults and teens 16 and older with partial-onset seizures, it can also be used as the sole medication after switching from another anti-seizure drug.
In children with Lennox-Gastaut syndrome, studies show that nearly half of patients experience a greater than 50% reduction in seizure frequency within three months of starting lamotrigine. One limitation: myoclonic seizures (brief, involuntary muscle jerks) tend not to improve with this medication.
Bipolar I Disorder Maintenance
Lamotrigine stands out among mood stabilizers for its strength in preventing the depressive side of bipolar disorder. It is FDA-approved for maintenance treatment of bipolar I disorder, meaning it is used after an acute mood episode has been treated to delay the return of future episodes.
An 18-month placebo-controlled trial published in JAMA Psychiatry found that lamotrigine was significantly better than placebo at preventing depressive episodes, but the difference for preventing manic episodes was not statistically significant. This makes lamotrigine particularly valuable for people whose bipolar disorder is dominated by depression rather than mania. Lithium, by comparison, tends to be stronger at preventing manic episodes, so the two medications complement each other.
Off-Label Uses in Psychiatry
Beyond its FDA-approved indications, lamotrigine is frequently prescribed off-label for bipolar II disorder, a condition where depressive episodes are the primary burden. Naturalistic studies and clinical data support its long-term benefit for bipolar II depression, with sustained improvement lasting up to a year in patients who added lamotrigine to their existing mood stabilizer. Because bipolar II lacks the full manic episodes that define bipolar I, and lamotrigine’s strength lies in preventing depression, this off-label use is common in clinical practice.
How Lamotrigine Works in the Brain
Lamotrigine calms overactive brain signaling through several mechanisms. Its primary action is blocking voltage-sensitive sodium channels, which neurons use to fire electrical signals. By binding to these channels when they are in an inactive state, lamotrigine makes it harder for neurons to fire rapidly and repeatedly, which is exactly what happens during a seizure.
It also reduces the release of glutamate, the brain’s main excitatory chemical messenger. Multiple studies have confirmed lower glutamate levels in brain tissue after lamotrigine treatment. Additionally, it inhibits certain calcium channels, which play a role in neurotransmitter release and intracellular signaling. This combination of effects on sodium channels, calcium channels, and glutamate release likely explains why lamotrigine works across such different conditions.
The Slow Start: Why Dosing Takes Weeks
Unlike many medications, lamotrigine cannot be started at its full dose. The FDA requires a gradual dose escalation over several weeks to minimize the risk of serious skin rashes, including Stevens-Johnson syndrome, a rare but potentially life-threatening reaction. Starter kits are available to guide the first five weeks of treatment.
The exact schedule depends on what other medications you take. If you are on valproate (a common seizure and mood medication), lamotrigine is started at just 25 mg every other day for the first two weeks, because valproate slows lamotrigine’s breakdown in the body and effectively doubles its levels. Without valproate, the typical starting dose is 25 mg daily. The dose is gradually increased over six to seven weeks until reaching the target, which for bipolar disorder is usually 200 mg daily. This slow titration requires patience, but it is a critical safety measure.
Serious Skin Rash Warning
Lamotrigine carries an FDA boxed warning for serious skin reactions. The incidence of rashes requiring hospitalization is approximately 0.08% to 0.3% in adults and 0.3% to 0.8% in children aged 2 to 17. These reactions include Stevens-Johnson syndrome and, in rare cases, toxic epidermal necrolysis.
Nearly all life-threatening rashes occur within 2 to 8 weeks of starting treatment, though isolated cases have appeared after six months. Factors that increase risk include taking valproate at the same time, starting at too high a dose, increasing the dose too quickly, and carrying a specific genetic variant called HLA-B*1502 (more common in people of Southeast Asian descent). Because it is impossible to predict whether a rash will become dangerous, the standard practice is to stop lamotrigine at the first sign of any rash unless it is clearly unrelated to the medication.
Common Side Effects
At typical doses, the most frequently reported side effects include dizziness, headache, double vision, unsteadiness, nausea, and blurred vision. These tend to be more common when lamotrigine is used alongside other seizure medications rather than on its own. Many of these side effects are dose-related and improve with time or dose adjustment.
Compared to many other mood stabilizers and anti-seizure medications, lamotrigine is generally considered well-tolerated. It is less likely to cause weight gain, sedation, or cognitive dulling, which are common complaints with alternatives like valproate or some older anti-seizure drugs. This tolerability profile is one reason it has become a first-line option for bipolar maintenance treatment.
Important Drug Interactions
Two interactions stand out for their clinical significance. Valproate inhibits the enzyme that breaks down lamotrigine, roughly doubling its blood levels. This is why the starting dose is halved when the two are taken together, and why the combination increases the risk of rash.
Estrogen-containing oral contraceptives work in the opposite direction, speeding up lamotrigine’s metabolism and potentially lowering its levels enough to reduce effectiveness. Women starting or stopping hormonal birth control may need their lamotrigine dose adjusted. Interestingly, when valproate and oral contraceptives are both present, valproate’s inhibitory effect counterbalances the contraceptive’s acceleration, and lamotrigine levels remain relatively stable.
Pregnancy also dramatically affects lamotrigine levels. In women on lamotrigine alone, clearance of the drug increases by roughly 295% by mid-pregnancy, often requiring significant dose increases to maintain seizure control or mood stability. This effect is much smaller in women also taking valproate, where clearance rises only about 60%.
Lamotrigine and Pregnancy
For women with epilepsy or bipolar disorder who become pregnant, lamotrigine is one of the more frequently used options because of its relatively favorable safety data. In a pregnancy registry tracking 414 first-trimester exposures to lamotrigine monotherapy, the major birth defect rate was 2.9%, which is close to the 2% to 3% baseline rate in the general population. This positions lamotrigine as one of the lower-risk choices among anti-seizure and mood-stabilizing medications during pregnancy, though no medication is entirely without risk.